PL3041831T3 - Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby - Google Patents

Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby

Info

Publication number
PL3041831T3
PL3041831T3 PL14767252T PL14767252T PL3041831T3 PL 3041831 T3 PL3041831 T3 PL 3041831T3 PL 14767252 T PL14767252 T PL 14767252T PL 14767252 T PL14767252 T PL 14767252T PL 3041831 T3 PL3041831 T3 PL 3041831T3
Authority
PL
Poland
Prior art keywords
alpha
compositions
salt forms
treating disease
tea salt
Prior art date
Application number
PL14767252T
Other languages
English (en)
Inventor
Michael O'neill
Barbara KIDON
Thomas Adkins
Hongqiao Wu
Emmanuel T. Akporiaye
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of PL3041831T3 publication Critical patent/PL3041831T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/723,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
PL14767252T 2013-09-06 2014-09-05 Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby PL3041831T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361874823P 2013-09-06 2013-09-06
PCT/US2014/054354 WO2015035212A1 (en) 2013-09-06 2014-09-05 Alpha-tea salt forms: compositions and uses for treating disease
EP14767252.1A EP3041831B1 (en) 2013-09-06 2014-09-05 Alpha-tea salt forms: compositions and uses for treating disease

Publications (1)

Publication Number Publication Date
PL3041831T3 true PL3041831T3 (pl) 2021-07-19

Family

ID=51570908

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14767252T PL3041831T3 (pl) 2013-09-06 2014-09-05 Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby

Country Status (9)

Country Link
US (2) US10370350B2 (pl)
EP (1) EP3041831B1 (pl)
JP (2) JP6675985B2 (pl)
AU (1) AU2014318014C1 (pl)
CA (1) CA2922375C (pl)
DK (1) DK3041831T3 (pl)
ES (1) ES2766324T3 (pl)
PL (1) PL3041831T3 (pl)
WO (1) WO2015035212A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041831B1 (en) 2013-09-06 2019-10-23 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
CN107050432B (zh) * 2017-02-28 2019-09-10 上海交通大学医学院 胃泌素在制备诊断和治疗乳腺癌药物中的应用
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
EP3646873A1 (en) * 2018-10-31 2020-05-06 Aprofol AG Folate salts
CN111635390A (zh) * 2020-06-30 2020-09-08 江南大学 一种低泡型α-生育酚表面活性剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4629734Y1 (pl) 1968-04-23 1971-10-14
JP2634047B2 (ja) 1985-10-15 1997-07-23 ザ リポソ−ム カンパニ−,インコ−ポレイテツド アルファトコフェロールをベースとした小胞体
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US6770672B1 (en) 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
IL142082A (en) * 1998-09-23 2005-12-18 Res Dev Tocoflowers, tocotrinols, derivatives as a novel and other side-chain and their uses
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
JP2004504268A (ja) 2000-02-11 2004-02-12 リサーチ ディベロップメント ファンデーション トコフェロール、トコトリエノール、その他のクロマン、及びそれらの側鎖誘導体とその利用法
AU2002361812B2 (en) 2001-12-19 2007-11-08 Research Development Foundation Liposomal delivery of vitamin E based compounds
EP3041831B1 (en) 2013-09-06 2019-10-23 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease

Also Published As

Publication number Publication date
ES2766324T3 (es) 2020-06-12
JP2016532714A (ja) 2016-10-20
EP3041831B1 (en) 2019-10-23
DK3041831T3 (da) 2020-01-27
JP2020063294A (ja) 2020-04-23
US20200148661A1 (en) 2020-05-14
US10370350B2 (en) 2019-08-06
CA2922375C (en) 2021-06-15
US20160214954A1 (en) 2016-07-28
AU2014318014B2 (en) 2018-06-07
JP6675985B2 (ja) 2020-04-08
AU2014318014C1 (en) 2018-11-15
EP3041831A1 (en) 2016-07-13
CA2922375A1 (en) 2015-03-12
US10934267B2 (en) 2021-03-02
AU2014318014A1 (en) 2016-03-17
WO2015035212A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
HK1225305A1 (zh) 治療腦疾病的方法和組合物
IL243976B (en) kdm1a inhibitors for disease treatment
ZA201505390B (en) Compositions and methods for treating pests
EP2991649A4 (en) COMPOSITIONS AND METHODS FOR TREATING STATES AND PSYCHIC DISEASES RELATED TO MICROBIOTA
SG11201507507PA (en) Compositions and methods for treating mpsi
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
HK1217650A1 (zh) 用於治療劇痛的組合物及方法
HK1214255A1 (zh) -醯基氨基噻唑衍生物或其鹽
EP2968377A4 (en) COMPOSITIONS AND METHODS OF TREATING INFECTION DISEASES
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
SG10201710538XA (en) Compositions and methods for treating skin
EP2968452A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NETWORK DISEASES
HK1215684A1 (zh) 毛髮處理劑組合物
HK1218883A1 (zh) 對神經毒劑的暴露的治療
HK1217715A1 (zh) 治療中風的組合物及方法
ZA201507015B (en) Composition for treating hemorrhoids
EP2968550A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS
ZA201407032B (en) Preventing or treating periodontal disease
GB201321628D0 (en) Treatment of disease
GB201302472D0 (en) Compositions and methods for treating biofilms
GB201302474D0 (en) Compositions and methods for treating biofilms
GB201302475D0 (en) Compositions and methods for treating biofilms